Their functional plasticity may allow transient switching to a “regulatory” pro-tumor phenotype owing to expression of cytokines such as TGFβ and IL-10, signaling modulatory states that could potentially influence clinical outcomes including toxicity and therapy response. This evidence concerns the gene TGFB1 and neoplasm.